NHMRC Areas of Funding

- Public Health
- Health Services
- Clinical Medicine
- Biomedical

NHMRC Research Expenditure by Broad Research Area:

- Health services: 9%
- Biomedical: 25%
- Clinical medicine: 1%
- Public health: 65%

NHMRC: Research Funding Facts Book 2011
Our Focus
Biomedical research and innovations

Our Mission
“To advance innovations in medical research related to the nature, prevention, diagnosis, treatment and incidence of disease and other health problems that have a significant impact on the health of humans”
Accessing Benefits from Medical Research

Community Benefits
- Devices
- Diagnostics
- Medicines
- Vaccines
- Biologicals
- Tools

Increasing need for collaboration
- Basic Research
- Applied Research
- Proof of Concept
- Pre-clinical
- Clinical
- Regulatory Approval
- Community Benefit

Biomedical
Advancing innovation

NFMRI is focused on supporting research that advances innovation.

Within three strategic portfolios NFMRI is looking to make social investments through grants where we can value-add and maximise the potential social return on investment.

We are actively seeking funding collaborations with donors, foundations, fund managers and government.
Concepts, discoveries and innovation

NFMRI supports
1. Young researchers, early discoveries and new paradigms need support to become competitive and stand on their own two feet.

2. Early original innovation and discovery research that does not receive NHMRC grants.

3. Supporting the validation of new concepts, discoveries and intellectual property creates the foundation for innovations and community benefits of tomorrow.
Strategic collaborations

Support for strategic collaborative research activities focussed on advancing innovations and validating directions is needed.

NFMRI is uniquely positioned to value-add to the advancement of research and innovations in preparation for potential collaborations.

By partnering with researchers NFMRI will support collaborative research activities undertaken by other research groups that expedite the advancement of the innovation and are important for attracting potential industry partners and investors.
Advancing Innovation: Portfolio 3

Bridging the ‘Valley of Death’

Often referred to as the ‘valley of death’ is the area where strategic research studies are required to attract potential investors and industry collaborators.

Traditional funding mechanisms do not support or motivate researchers to contract research activities necessary to answer some research questions necessary to form these collaborations.

These research questions are often not attractive to publications as they are “less newsworthy” and not research undertaken by the chief investigator and their team.

By supporting small, incremental studies NFMRI can manage risk and make innovations more attractive to potential commercial partners and investors.
Partnering opportunities

Our partnering opportunities are focused around the three research portfolios.

By partnering with researchers to provide support and knowledge we aim to maximise the social returns from our support.

By partnering with grant-makers we can identify, evaluate and support innovative quality research projects with agreed impact objectives.

Advancing medical innovations needs more than dollars. Our culture is one where we consider our ability to value-add and advance innovations with the potential to attract future collaborators and deliver community benefits.
About NFMRI

Founded: 1977

DGR1 and TCC status

Auditors: Deloitte Touche Tohmatsu Limited

Fund managers: BT Financial Group

www.nfmri.org.au

Management
Dr Noel Chambers (CEO)
Ms Vanessa Chase

Board
Mr J Harkness (Chairman)
Dr J Dixon Hughes OAM
Dr V Cowlishaw Shortell
Dr K Hellestrand
Dr R Garrick
Dr J Graham
Mr A McGrath
Ms J Schwager AO
Mr K Drewery

Research Advisory Committee
Dr J Dixon Hughes OAM (Chairman)
Dr R Garrick
Professor D Burke
Professor Y Cossart
Professor S McCarthy
Contact us

Dr. Noel Chambers
Chief Executive Officer

nchambers@nfmri.org.au
0412 357 893

www.nfmri.org.au